Selective JAK2 Pathway Inhibition Enhances Anti-Leukemic Functionality in CD19 CAR-T Cells

0
105
The authors explored the combinatorial use of a selective type II JAK2 inhibitor, CHZ868, with CD19 CAR-T cells, revealing a synergistic enhancement of anti-leukemic activity across B-cell tumor models irrespective of JAK2 mutational status.
[Cancer Immunology Immunotherapy]
Full Article